|
KMID : 1039120200090010040
|
|
Clinical and Experimental Vaccine Research
2020 Volume.9 No. 1 p.40 ~ p.47
|
|
|
Immunogenicity of a new, inactivated canine adenovirus type 2 vaccine for dogs
|
|
Yang Dong-Kun
Kim Ha-Hyun
Yoo Jae-Young
Ji Mi-Ryeon
Han Bok-Hee
Oh Su-Bin
Hyun Bang-Hun
|
|
|
Abstract
|
|
|
Purpose: We constructed a new canine adenovirus type 2 (CAV-2) vaccine candidate using the recently isolated Korean CAV-2 strain; we termed the vaccine APQA1701-40P and evaluated its safety and immunogenicity in dogs.
Materials and Methods: To generate the anti-CAV-2 vaccine, APQA1701 was passaged 40 times in MDCK cells growing in medium containing 5 mM urea and the virus was inactivated using 0.05% (volume per volume) formaldehyde. Two vaccines were prepared by blending inactivated APQA1701-40P with two different adjuvants; both were intramuscularly injected (twice) into guinea pigs. The safety and immunogenicity of the Cabopol-adjuvanted vaccine were evaluated in seronegative dogs. The humoral responses elicited were measured using an indirect enzyme-linked immunosorbent assay (I-ELISA), and via a virus neutralization assay (VNA).
Results: The new, inactivated CAV-2 vaccine strain, APQA1701-40P, lacked six amino acids of the E1b-19K protein. In guinea pigs, the Cabopol-adjuvanted vaccine afforded a slightly higher VNA titer and I-ELISA absorbance than an IMS gel-adjuvanted vaccine 4 weeks post-vaccination (p>0.05). Dogs inoculated with the former vaccine developed a significantly higher immune titer than non-vaccinated dogs.
Conclusion: The Cabopol-adjuvanted, inactivated CAV-2 vaccine was safe and induced a high VNA titer in dogs.
|
|
|
KEYWORD
|
|
|
Canine adenovirus type 2, Vaccine, Adjuvant
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|